Stocks of Zevra Therapeutics Inc (NASDAQ:ZVRA) traded higher last session on Wall Street, up 1.42% to $7.15.
ZVRA stock price is now -6.37% away from the 50-day moving average and -7.28% away from the 200-day moving average. The market capitalization of the company currently stands at $386.93M.
On October 07, 2024, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $20, while ‘Maxim Group’ rates the stock as ‘Buy’
In other news, Watton Corey Michael, Director bought 300 shares of the company’s stock on Mar 28 ’25. The stock was bought for $2,352 at an average price of $7.84. Upon completion of the transaction, the Director now directly owns 1,800 shares in the company, valued at $12870.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 19 ’25, Director Bode John B bought 10,000 shares of the business’s stock. A total of $79,624 was incurred on buying the stock at an average price of $7.96. This leaves the insider owning 40,000 shares of the company worth $0.29 million. A total of 1.08% of the company’s stock is owned by insiders.
During the past 12 months, Zevra Therapeutics Inc has had a low of $4.20 and a high of $9.76. As of last week, the company has a debt-to-equity ratio of 1.52, a current ratio of 2.53, and a quick ratio of 2.47. The fifty day moving average price for ZVRA is $7.6368 and a two-hundred day moving average price translates $7.720125 for the stock.
The latest earnings results from Zevra Therapeutics Inc (NASDAQ: ZVRA) was released for 2024-12-31. The net profit margin was -446.85% and return on equity was -207.84% for ZVRA. The company reported revenue of $12.04 million for the quarter, compared to $12.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.79 percent.
